0.037693
0.025281
0.005782
0.000000
0.041780
0.002293
0.000000
0.000000
0.111288
0.00000
0.00000
0.00000
Snook, C.F.
Wallace, B.A.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
2
88.90
96.64
123.85
26.530
28.820
9.060
C2 H4 O
44.053
ACETYL GROUP
non-polymer
C4 H9 N O2
103.120
n
ALPHA-AMINOISOBUTYRIC ACID
L-peptide linking
C5 H11 N O2
117.146
D-ISOVALINE
D-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C5 H9 N O3
131.130
n
4-HYDROXYPROLINE
HYDROXYPROLINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C H4 O
32.042
METHANOL
non-polymer
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C9 H13 N O
151.206
n
L-PHENYLALANINOL
bound form of Phenylalaninal
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
UK
Structure
STRUE6
2005
0969-2126
6
783
10.1016/S0969-2126(98)00079-3
9655831
The Structure and Function of Antiamoebin I, a Proline-Rich Membrane-Active Polypeptide.
1998
DK
Acta Crystallogr.,Sect.D
ABCRE6
0766
0907-4449
55
1539
10.1107/S0907444999007921
10489449
The Molecular-Replacement Solution of an Intermediate-Sized Helical Polypeptide, Antiamoebin I.
1999
London : University of London (Thesis)
Thesis, University of London
The Structure and Function of Antiamoebin I, a Membrane-Active Peptide
1997
London : University of London (Thesis)
Thesis, University of London
Molecular Redundancy and Protein Crystallography : X-Ray Structure Analysis of Antiamoebin I, Bovine Pancreatic Polypeptide and Human Serum Amyloid P Component
1988
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
293
1
DIFFRACTOMETER
1986
HILGER-WATTS
NI FILTER
M
x-ray
1
1.5418
1.0
1.5418
SEALED TUBE
1654.991
ANTIAMOEBIN I
2
nat
polymer
32.042
METHANOL
23
syn
non-polymer
no
yes
(ACE)F(AIB)(AIB)(AIB)(DIV)GL(AIB)(AIB)(HYP)Q(DIV)(HYP)(AIB)P(PHL)
XFAAAVGLAAPQVPAPF
A,B
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
sample
45244
EMERICELLOPSIS
1
1.71
28.00
USED NORMALISED STRUCTURE FACTORS
chem_comp
pdbx_database_status
refine
reflns
struct_conn
repository
Initial release
Version format compliance
Version format compliance
Atomic model
Database references
Derived calculations
Non-polymer description
Structure summary
Other
Data collection
Derived calculations
Other
Refinement description
Structure summary
1
0
1999-01-20
1
1
2011-06-14
1
2
2011-07-13
1
3
2011-07-27
1
4
2012-12-12
1
5
2020-03-04
_chem_comp.pdbx_synonyms
_pdbx_database_status.process_site
_refine.ls_R_factor_obs
_refine.ls_number_reflns_obs
_reflns.pdbx_Rmerge_I_obs
_struct_conn.pdbx_leaving_atom_flag
CRYSTAL STRUCTURE OF THE PEPTAIBOL TRICHOTOXIN_A50E
SOLUTION STRUCTURE OF THE PEPTAIBOL ZERVAMICIN IIB IN METHANOL
SOLUTION STRUCTURE OF THE PEPTIABOL ZERVAMICIN IIB
SOLUTION STRUCTURE OF THE PEPTAIBOL ZERVAMICIN IIB BOUND TO DPC MICELLES
SOLUTION STRUCTURE OF THE PEPTAIBOL ANTIAMOEBIN I
CRYSTAL STRUCTURE OF THE PEPTAIBOL ALAMETHICIN
SOLUTION STRUCTURE OF THE PEPTAIBOL CHRYSOSPERMIN C BOUND TO DPC MICELLES
CRYSTAL STRUCTURE OF THE PEPTAIBOL CEPHAIBOL C
CRYSTAL STRUCTURE OF THE PEPTAIBOL CEPHAIBOL B
CRYSTAL STRUCTURE OF THE PEPTAIBOL CEPHAIBOL A
Y
BNL
1997-10-11
REL
MOH
METHANOL
ANTIAMOEBIN I IS LINEAR PEPTIDE, A MEMBER OF THE PEPTAIBOL
FAMILY OF MEMBRANE CHANNEL FORMING PEPTIDES.
HERE, ANTIAMOEBIN I IS REPRESENTED BY THE SEQUENCE (SEQRES)
Antibiotic
ANTIAMOEBIN I IS A HEXADECAMERIC HELICAL PEPTIDE.
THE N-TERM IS ACETYLATED (RESIDUE 0)
Antiamoebin 1
Peptaibol
MOH
18
2
MOH
MOH
18
A
MOH
19
2
MOH
MOH
19
A
MOH
20
2
MOH
MOH
20
A
MOH
21
2
MOH
MOH
21
A
MOH
22
2
MOH
MOH
22
A
MOH
23
2
MOH
MOH
23
A
MOH
24
2
MOH
MOH
24
A
MOH
25
2
MOH
MOH
25
A
MOH
26
2
MOH
MOH
26
A
MOH
27
2
MOH
MOH
27
A
MOH
28
2
MOH
MOH
28
A
MOH
18
2
MOH
MOH
18
B
MOH
19
2
MOH
MOH
19
B
MOH
20
2
MOH
MOH
20
B
MOH
21
2
MOH
MOH
21
B
MOH
22
2
MOH
MOH
22
B
MOH
23
2
MOH
MOH
23
B
MOH
24
2
MOH
MOH
24
B
MOH
25
2
MOH
MOH
25
B
MOH
26
2
MOH
MOH
26
B
MOH
27
2
MOH
MOH
27
B
MOH
28
2
MOH
MOH
28
B
MOH
29
2
MOH
MOH
29
B
ACE
0
n
1
ACE
0
A
PHE
1
n
2
PHE
1
A
AIB
2
n
3
AIB
2
A
AIB
3
n
4
AIB
3
A
AIB
4
n
5
AIB
4
A
DIV
5
n
6
DIV
5
A
GLY
6
n
7
GLY
6
A
LEU
7
n
8
LEU
7
A
AIB
8
n
9
AIB
8
A
AIB
9
n
10
AIB
9
A
HYP
10
n
11
HYP
10
A
GLN
11
n
12
GLN
11
A
DIV
12
n
13
DIV
12
A
HYP
13
n
14
HYP
13
A
AIB
14
n
15
AIB
14
A
PRO
15
n
16
PRO
15
A
PHL
16
n
17
PHL
16
A
ACE
0
n
1
ACE
0
B
PHE
1
n
2
PHE
1
B
AIB
2
n
3
AIB
2
B
AIB
3
n
4
AIB
3
B
AIB
4
n
5
AIB
4
B
DIV
5
n
6
DIV
5
B
GLY
6
n
7
GLY
6
B
LEU
7
n
8
LEU
7
B
AIB
8
n
9
AIB
8
B
AIB
9
n
10
AIB
9
B
HYP
10
n
11
HYP
10
B
GLN
11
n
12
GLN
11
B
DIV
12
n
13
DIV
12
B
HYP
13
n
14
HYP
13
B
AIB
14
n
15
AIB
14
B
PRO
15
n
16
PRO
15
B
PHL
16
n
17
PHL
16
B
0.136
0.156
3567
author_defined_assembly
1
monomeric
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
C
MOH
23
H
C
MOH
1
1
N
1
A
C
MOH
24
I
C
MOH
1
1
N
1
A
C
MOH
25
J
C
MOH
1
1
N
1
A
C
MOH
26
K
C
MOH
1
1
N
1
A
C
MOH
28
M
C
MOH
1
1
N
1
B
C
MOH
20
P
C
MOH
1
1
N
1
B
C
MOH
21
Q
C
MOH
1
1
N
1
B
C
MOH
22
R
C
MOH
1
1
N
1
B
C
MOH
24
T
C
MOH
1
1
N
1
B
C
MOH
25
U
C
MOH
1
1
N
1
B
C
MOH
26
V
C
MOH
1
1
N
1
B
C
MOH
27
W
C
MOH
1
1
N
1
B
C
MOH
28
X
C
MOH
1
1
N
1
B
C
MOH
29
Y
C
MOH
1
1
N
1
B
B
CB
O
PHL
MOH
16
23
0.81
1
B
B
CA
O
PHL
MOH
16
23
2.17
1
20.34
2.50
121.70
142.04
B
B
B
C
N
CA
PHE
AIB
AIB
1
2
2
Y
1
A
B
O
O
MOH
MOH
27
28
1.99
1_555
1_554
1
A
A
C
C
PHL
MOH
16
18
2.10
1_555
1_556
1
B
AIB
2
-137.07
-53.93
REFINEMENT STARTED USING 10.0 TO 2.5A AND DATA CUT-OFF AT 2 SIGMA IN X-PLOR. HIGH RESOLUTION LIMIT INCREASED TO 2.0A, LOW RESOLUTION DECREASED TO 25.0A AND DATA CUT-OFF DECREASED TO 0.0 SIGMA AT 2.0A RESOLUTION. RESOLUTION INCREASED FROM 2.0A TO 1.4A WITH ALL DATA USING SHELXL-93. REFINEMENT CEASED AFTER RESIDUES 1 TO 5 IN B-CHAIN IDENTIFIED AS DISORDERED IN DENSITY.
0.156
0.156
1.40
25.00
1074
4359
4359
982
95.4
1
0.000
MOLECULAR REPLACEMENT
RESIDUES 6 - 16 OF LEU1-ZERVAMICIN WITH ALL NON -EQUIVALENT SIDE-CHAINS TRIMMED TO ALA.
HETATM DATA FROM CCSD
ENGH AND HUBER
268.00
1.40
25.00
0
268
30
0
238
0.036
3.152
0.000
0.000
0.000
0.000
0.016
0.005
0.022
0.065
1.200
25.000
1JOH
6715
0.000
0.0120000
1
10.5000
1.000
93.7
model building
SHELXL-93
refinement
SHELXL-93
phasing
SHELXL-93
ANTIAMOEBIN I
THE STRUCTURE OF ANTIAMOEBIN I, A MEMBRANE-ACTIVE PEPTIDE
1
N
N
1
N
N
2
N
N
2
N
N
2
N
N
2
N
N
2
N
N
2
N
N
2
N
N
2
N
N
2
N
N
2
N
N
2
N
N
2
N
N
2
N
N
2
N
N
2
N
N
2
N
N
2
N
N
2
N
N
2
N
N
2
N
N
2
N
N
2
N
N
2
N
N
A
PHE
1
A
PHE
2
HELX_P
A
HYP
10
A
HYP
11
1
1
10
B
AIB
2
B
AIB
3
HELX_P
B
HYP
10
B
HYP
11
1
2
9
covale
1.342
both
A
ACE
0
A
C
ACE
1
1_555
A
PHE
1
A
N
PHE
2
1_555
covale
1.321
both
A
PHE
1
A
C
PHE
2
1_555
A
AIB
2
A
N
AIB
3
1_555
covale
1.334
both
A
AIB
2
A
C
AIB
3
1_555
A
AIB
3
A
N
AIB
4
1_555
covale
1.311
both
A
AIB
3
A
C
AIB
4
1_555
A
AIB
4
A
N
AIB
5
1_555
covale
1.343
both
A
AIB
4
A
C
AIB
5
1_555
A
DIV
5
A
N
DIV
6
1_555
covale
1.333
both
A
DIV
5
A
C
DIV
6
1_555
A
GLY
6
A
N
GLY
7
1_555
covale
1.320
both
A
LEU
7
A
C
LEU
8
1_555
A
AIB
8
A
N
AIB
9
1_555
covale
1.337
both
A
AIB
8
A
C
AIB
9
1_555
A
AIB
9
A
N
AIB
10
1_555
covale
1.320
both
A
AIB
9
A
C
AIB
10
1_555
A
HYP
10
A
N
HYP
11
1_555
covale
1.307
both
A
HYP
10
A
C
HYP
11
1_555
A
GLN
11
A
N
GLN
12
1_555
covale
1.336
both
A
GLN
11
A
C
GLN
12
1_555
A
DIV
12
A
N
DIV
13
1_555
covale
1.311
both
A
DIV
12
A
C
DIV
13
1_555
A
HYP
13
A
N
HYP
14
1_555
covale
1.323
both
A
HYP
13
A
C
HYP
14
1_555
A
AIB
14
A
N
AIB
15
1_555
covale
1.309
both
A
AIB
14
A
C
AIB
15
1_555
A
PRO
15
A
N
PRO
16
1_555
covale
1.315
both
A
PRO
15
A
C
PRO
16
1_555
A
PHL
16
A
N
PHL
17
1_555
covale
1.760
none
A
PHL
16
A
O
PHL
17
1_554
A
MOH
18
C
C
MOH
1_555
covale
1.760
none
A
PHL
16
A
O
PHL
17
1_555
A
MOH
18
C
C
MOH
1_556
covale
1.333
both
B
ACE
0
B
C
ACE
1
1_555
B
PHE
1
B
N
PHE
2
1_555
covale
1.289
both
B
PHE
1
B
C
PHE
2
1_555
B
AIB
2
B
N
AIB
3
1_555
covale
1.322
both
B
AIB
2
B
C
AIB
3
1_555
B
AIB
3
B
N
AIB
4
1_555
covale
1.356
both
B
AIB
3
B
C
AIB
4
1_555
B
AIB
4
B
N
AIB
5
1_555
covale
1.323
both
B
AIB
4
B
C
AIB
5
1_555
B
DIV
5
B
N
DIV
6
1_555
covale
1.346
both
B
DIV
5
B
C
DIV
6
1_555
B
GLY
6
B
N
GLY
7
1_555
covale
1.339
both
B
LEU
7
B
C
LEU
8
1_555
B
AIB
8
B
N
AIB
9
1_555
covale
1.350
both
B
AIB
8
B
C
AIB
9
1_555
B
AIB
9
B
N
AIB
10
1_555
covale
1.316
both
B
AIB
9
B
C
AIB
10
1_555
B
HYP
10
B
N
HYP
11
1_555
covale
1.321
both
B
HYP
10
B
C
HYP
11
1_555
B
GLN
11
B
N
GLN
12
1_555
covale
1.320
both
B
GLN
11
B
C
GLN
12
1_555
B
DIV
12
B
N
DIV
13
1_555
covale
1.345
both
B
DIV
12
B
C
DIV
13
1_555
B
HYP
13
B
N
HYP
14
1_555
covale
1.310
both
B
HYP
13
B
C
HYP
14
1_555
B
AIB
14
B
N
AIB
15
1_555
covale
1.301
both
B
AIB
14
B
C
AIB
15
1_555
B
PRO
15
B
N
PRO
16
1_555
covale
1.314
both
B
PRO
15
B
C
PRO
16
1_555
B
PHL
16
B
N
PHL
17
1_555
covale
1.649
none
B
PHL
16
B
CG
PHL
17
1_555
B
MOH
23
S
O
MOH
1_555
covale
1.844
none
B
MOH
19
O
C
MOH
1_555
A
MOH
27
L
O
MOH
1_555
ANTIBIOTIC
ANTIAMOEBIN I, PEPTAIBOL, ANTIBACTERIAL, ANTIFUNGAL, ANTIBIOTIC
given
0.000000
1.000000
0.000000
1.000000
0.000000
0.000000
0.000000
0.000000
-1.000000
0.00000
0.00000
115.46000
NOR00945
NOR
1
NOR00945
0
16
1JOH
0
16
NOR00945
A
1
1
17
0
16
1JOH
0
16
NOR00945
B
1
1
17
BINDING SITE FOR CHAIN A OF ANTIAMOEBIN I
Software
9
BINDING SITE FOR CHAIN B OF ANTIAMOEBIN I
Software
9
B
PHE
1
B
PHE
2
9
1_446
B
PHE
1
B
PHE
2
9
1_445
B
GLY
6
B
GLY
7
9
1_555
B
LEU
7
B
LEU
8
9
1_556
B
AIB
9
B
AIB
10
9
1_555
B
HYP
10
B
HYP
11
9
1_556
B
HYP
10
B
HYP
11
9
1_555
B
GLN
11
B
GLN
12
9
1_556
B
PHL
16
B
PHL
17
9
1_455
A
DIV
5
A
DIV
6
9
1_664
A
GLY
6
A
GLY
7
9
1_554
A
LEU
7
A
LEU
8
9
1_555
A
AIB
8
A
AIB
9
9
1_665
A
AIB
9
A
AIB
10
9
1_554
A
HYP
10
A
HYP
11
9
1_555
A
HYP
10
A
HYP
11
9
1_554
A
GLN
11
A
GLN
12
9
1_555
A
PHL
16
A
PHL
17
9
1_655
1
P 1